{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T14:45:59Z","timestamp":1785422759373,"version":"3.56.0"},"reference-count":17,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009687","name":"Wroclaw Medical University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009687","id-type":"DOI","asserted-by":"crossref"}]},{"id":[{"id":"https:\/\/ror.org\/01qpw1b93","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Long-term real-world data on dupilumab effectiveness and response trajectories in paediatric atopic dermatitis (AD) remain limited. This study evaluated long-term effectiveness, safety, response durability, and treatment trajectories in paediatric patients with moderate-to-severe AD treated with dupilumab. Methods: This retrospective single-centre cohort study included 55 paediatric patients with moderate-to-severe AD treated with dupilumab. Clinical outcomes, including Eczema Area and Severity Index (EASI), body surface area (BSA), and Children\u2019s Dermatology Life Quality Index (CDLQI), were assessed longitudinally throughout treatment. The primary endpoint was the achievement of EASI-75 over the course of treatment, including timing of response onset. Secondary endpoints included EASI-90 achievement, longitudinal changes in disease severity and quality of life, treatment durability, safety, and response trajectory analyses. Patients were additionally classified into mutually exclusive trajectory groups based on timing and durability of EASI-75 achievement. Results: Dupilumab treatment was associated with rapid and sustained clinical improvement. Some patients achieved EASI-75 as early as week 4, highlighting interindividual variability in response kinetics. At week 16, EASI-75 was achieved in 85.5% of patients and EASI-90 in 47.3%. Clinical effectiveness further improved during long-term follow-up, with EASI-75 achieved in 96.2% and EASI-90 in 86.5% of patients at the last available follow-up. Median CDLQI decreased from 22.0 at baseline to 3.0 during follow-up, indicating marked improvement in quality of life. Most patients (83.6%) were classified as early responders, while 10.9% demonstrated delayed but clinically meaningful improvement during continued treatment. Loss of response after initial EASI-75 achievement was uncommon (3.7%). Adverse events were predominantly mild, with eosinophilia and conjunctivitis representing the most frequently observed findings. Conclusions: Overall, dupilumab demonstrated high long-term effectiveness and favourable tolerability in paediatric patients with moderate-to-severe AD. Trajectory analyses revealed clinically meaningful heterogeneity in response kinetics despite favourable long-term outcomes, highlighting that delayed responders may still achieve substantial benefit during continued therapy.<\/jats:p>","DOI":"10.3390\/jcm15134862","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T03:09:17Z","timestamp":1782270557000},"page":"4862","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-Term Real-World Effectiveness and Response Trajectories of Dupilumab in Paediatric Atopic Dermatitis"],"prefix":"10.3390","volume":"15","author":[{"given":"Ma\u0142gorzata","family":"Ponikowska","sequence":"first","affiliation":[{"name":"Centre of General Dermatology and Oncodermatology, Wroclaw Medical University, 50-556 Wroclaw, Poland"},{"name":"University Centre of General and Oncological Dermatology, University Clinical Hospital in Wroclaw, Borowska 213, 50-556 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9100-9321","authenticated-orcid":false,"given":"Emilia","family":"Kucharczyk","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Wroclaw Medical University, 50-367 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7879-8305","authenticated-orcid":false,"given":"Karol","family":"Bili\u0144ski","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Wroclaw Medical University, 50-367 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1717-4280","authenticated-orcid":false,"given":"Danuta","family":"Nowicka","sequence":"additional","affiliation":[{"name":"Centre of General Dermatology and Oncodermatology, Wroclaw Medical University, 50-556 Wroclaw, Poland"},{"name":"University Centre of General and Oncological Dermatology, University Clinical Hospital in Wroclaw, Borowska 213, 50-556 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7624-631X","authenticated-orcid":false,"given":"\u0141ukasz","family":"Lewandowski","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Immunochemistry, Faculty of Medicine, Wroclaw Medical University, 50-368 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/bjd.19580","article-title":"The Global Burden of Atopic Dermatitis: Lessons from the Global Burden of Disease Study 1990\u20132017","volume":"184","author":"Laughter","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Artusa, S., Mazzuca, G., Piacentini, G., Castagnoli, R., Marseglia, G.L., Pietrobelli, A., and Pecoraro, L. (2024). Paediatric Atopic Dermatitis: The Unexpected Impact on Life with a Specific Look at the Molecular Level. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25094778"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/j.1742-1241.2006.01047.x","article-title":"Quality of Life and Childhood Atopic Dermatitis: The Misery of Living with Childhood Eczema","volume":"60","year":"2006","journal-title":"Int. J. Clin. Pract."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1111\/jdv.18429","article-title":"European Guideline (EuroGuiDerm) on Atopic Eczema-Part II: Non-Systemic Treatments and Treatment Recommendations for Special AE Patient Populations","volume":"36","author":"Wollenberg","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrd4624","article-title":"Targeting Key Proximal Drivers of Type 2 Inflammation in Disease","volume":"15","author":"Gandhi","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e13899","DOI":"10.1111\/cts.13899","article-title":"Dupilumab: Mechanism of Action, Clinical, and Translational Science","volume":"17","author":"McCann","year":"2024","journal-title":"Clin. Transl. Sci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s11882-024-01145-x","article-title":"Comparison of Old and New Systemic Treatments for Moderate to Severe Atopic Dermatitis","volume":"24","author":"Yim","year":"2024","journal-title":"Curr. Allergy Asthma Rep."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S0140-6736(22)01539-2","article-title":"Dupilumab in Children Aged 6 Months to Younger than 6 Years with Uncontrolled Atopic Dermatitis: A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial","volume":"400","author":"Paller","year":"2022","journal-title":"Lancet"},{"key":"ref_9","unstructured":"European Medicines Agency (2024). Dupixent (Dupilumab) Summary of Product Characteristics."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2246602","DOI":"10.1080\/09546634.2023.2246602","article-title":"A 52-Week Multicenter Retrospective Real-World Study on Effectiveness and Safety of Dupilumab in Children with Atopic Dermatitis Aged from 6 to 11 Years","volume":"34","author":"Patruno","year":"2023","journal-title":"J. Dermatol. Treat."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s40272-022-00531-0","article-title":"Dupilumab Treatment in Children Aged 6\u201311 Years with Atopic Dermatitis: A Multicentre, Real-Life Study","volume":"24","author":"Napolitano","year":"2022","journal-title":"Paediatr. Drugs"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1001\/jamadermatol.2019.3336","article-title":"Efficacy and Safety of Dupilumab in Adolescents with Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial","volume":"156","author":"Simpson","year":"2020","journal-title":"JAMA Dermatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s40257-022-00683-2","article-title":"Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE)","volume":"23","author":"Blauvelt","year":"2022","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/j.jaci.2017.01.011","article-title":"The Immunology of Atopic Dermatitis and Its Reversibility with Broad-Spectrum and Targeted Therapies","volume":"139","author":"Brunner","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1111\/bjd.19460","article-title":"Dupilumab Provides Favourable Long-Term Safety and Efficacy in Children Aged \u22656 to <12 Years with Uncontrolled Severe Atopic Dermatitis: Results from an Open-Label Phase IIa Study and Subsequent Phase III Open-Label Extension Study","volume":"184","author":"Cork","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/j.jaci.2021.01.013","article-title":"Biomarkers in Atopic Dermatitis\u2014A Review on Behalf of the International Eczema Council","volume":"147","author":"Thyssen","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1177\/2040622318773686","article-title":"Dupilumab in Atopic Dermatitis: Rationale, Latest Evidence and Place in Therapy","volume":"9","author":"Bakker","year":"2018","journal-title":"Ther. Adv. Chronic Dis."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/13\/4862\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T04:56:10Z","timestamp":1782536170000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/13\/4862"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":17,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["jcm15134862"],"URL":"https:\/\/doi.org\/10.3390\/jcm15134862","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]}}}